We consistently identified signatures corresponding to the tumour‐promoting inflammation and avoiding immune destruction hallmarks (T cell activation, NK‐cell activation and complement cascade activation), the evading growth suppressors (ATM, Rb and G1 to S phase transition signalling), the inducing angiogenesis (angiogenesis signalling), the sustained proliferative signalling (BRAF‐ERK‐CREB1), the activating invasion and metastasis (ECM receptor signalling and EMT markers), and the genome instability and mutation (histone modification) hallmarks. The gene discussed is CREB1; the disease is neoplasm.